Iterum <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Q1 2025 Financial Results with Non-GAAP Net Loss Adjustments; Prepares for ORLYNVAHTM Launch by Q4 2025
Iterum Therapeutics plc, a company focused on delivering next-generation oral and IV antibiotics, reported its financial results for the first quarter ended March 31, 2025. The company noted a GAAP net loss but did not provide a specific figure. Iterum also disclosed non-GAAP financial measures, excluding certain expenses such as intangible asset amortization, share-based compensation, and adjustments related to financial instruments, which were detailed in the reconciliation tables provided. The company is preparing for the potential launch of ORLYNVAHTM, an antibiotic for uncomplicated urinary tract infections, by the fourth quarter of 2025. Additionally, Iterum has extended its cash runway into 2026, indicating a strengthened financial position to support its strategic objectives. The financial results focused on the company's operational goals, with no specific mention of variations in sales or revenue figures compared to previous periods.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-069794), on May 13, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。